Literature DB >> 8907063

Retroperitoneal fibrosis. A true connective tissue disease.

G S Gilkeson1, N B Allen.   

Abstract

Retroperitoneal fibrosis, a disease that can occur at any age, is characterized by a periaortic fibrous mass that often surrounds the ureters, leading to ureteral obstruction. Patients who present with this disease may complain of flank pain and acute renal failure. There is a high correlation with atherosclerotic disease of the aorta, although the pathogenesis of this disease remains unknown. Although recommendations for therapy remain empiric, prednisone seems to be efficacious in treatment; tamoxifen also may be effective. Retroperitoneal fibrosis usually does not lead to long-term morbidity or affect survival.

Entities:  

Mesh:

Year:  1996        PMID: 8907063     DOI: 10.1016/s0889-857x(05)70260-x

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  26 in total

1.  [¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience.

Authors:  Francesco Bertagna; Giorgio Treglia; Lucia Leccisotti; Giovanni Bosio; Federica Motta; Alessandro Giordano; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2012-03-16       Impact factor: 2.374

2.  Retroperitoneal fibrosis and c-ANCA positivity.

Authors:  Clio P Mavragani; Michalis Voulgarelis
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

3.  Abdominal inflammatory masses mimicking neoplasia in children-experience of two centers.

Authors:  Piotr Czauderna; Klaus Schaarschmidt; Leszek Komasara; Dieter Harms; Michael Lempe; Klaus Vorpahl; Malgorzata Szumera; Alicja Balanda
Journal:  Pediatr Surg Int       Date:  2005-04-07       Impact factor: 1.827

Review 4.  Retroperitoneal fibrosis: a clinical and outcome analysis of 58 cases and review of literature.

Authors:  Hang Liu; Gejun Zhang; Yimeng Niu; Nan Jiang; Weiguo Xiao
Journal:  Rheumatol Int       Date:  2014-04-23       Impact factor: 2.631

Review 5.  Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review.

Authors:  Giorgio Treglia; Maria Vittoria Mattoli; Francesco Bertagna; Raffaele Giubbini; Alessandro Giordano
Journal:  Rheumatol Int       Date:  2012-11-05       Impact factor: 2.631

6.  The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.

Authors:  Gabriella Moroni; Massimo Castellani; Aurora Balzani; Roberto Dore; Nicola Bonelli; Selena Longhi; Isabella Martinelli; Piergiorgio Messa; Paolo Gerundini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

7.  Retroperitoneal fibrosis as a cause of positive FDG PET/CT.

Authors:  Amar Mehta; Todd M Blodgett
Journal:  J Radiol Case Rep       Date:  2011-07-01

8.  Chylous ascites as a consequence of idiopathic pancreatitis.

Authors:  Chwanrow Karim Baban; Michael Murphy; Cristóir O'Sulleabháin; Deirdre O'Hanlon
Journal:  BMJ Case Rep       Date:  2014-02-05

9.  (18)F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis.

Authors:  R Fernández-López; J A Lojo; I Acevedo-Báñez; R González-León; I Borrego-Dorado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-01       Impact factor: 9.236

10.  Tamoxifen in the treatment of idiopathic retroperitoneal fibrosis.

Authors:  Ihsan Ergun; Kenan Keven; Basol Canbakan; Yakup Ekmekci; Bulent Erbay
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.